FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922249564> ?p ?o ?g. }

• W2922249564 endingPage "2775" @default.
• W2922249564 startingPage "2765" @default.
• W2922249564 abstract "Abstract This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given with obinutuzumab and its safety and tolerability in patients with relapsed/refractory (R/R) or previously untreated (first line [1L]) chronic lymphocytic leukemia (CLL). Venetoclax dose initially was escalated (100-400 mg) in a 3 + 3 design to define MTD combined with standard-dose obinutuzumab. Patients received venetoclax (schedule A) or obinutuzumab (schedule B) first to compare safety and determine dose/schedule for expansion. Venetoclax-obinutuzumab was administered for 6 cycles, followed by venetoclax monotherapy until disease progression (R/R) or fixed duration 1-year treatment (1L). Fifty R/R and 32 1L patients were enrolled. No dose-limiting toxicities were observed. Safety, including incidence of tumor lysis syndrome (TLS), did not differ between schedules (2 laboratory TLSs per schedule). Schedule B and a 400-mg dose of venetoclax were chosen for expansion. The most common grade 3-4 adverse event was neutropenia (R/R, 58% of patients; 1L, 53%). Rates of grade 3-4 infections were 29% (R/R) and 13% (1L); no fatal infections occurred in 1L. All infusion-related reactions were grade 1-2, except for 2 grade 3 events. No clinical TLS was observed. Overall best response rate was 95% in R/R (complete response [CR]/CR with incomplete marrow recovery [CRi], 37%) and 100% in 1L (CR/CRi, 78%) patients. Rate of undetectable (&lt;10−4) minimal residual disease (uMRD) in peripheral blood for R/R and 1L patients, respectively, was 64% and 91% ≥3 months after last obinutuzumab dose. Venetoclax and obinutuzumab therapy had an acceptable safety profile and elicited durable responses and high rates of uMRD. This trial was registered at www.clinicaltrials.gov as #NCT01685892." @default.
• W2922249564 created "2019-03-22" @default.
• W2922249564 creator A5000959540 @default.
• W2922249564 creator A5013649293 @default.
• W2922249564 creator A5013974745 @default.
• W2922249564 creator A5014844829 @default.
• W2922249564 creator A5016734314 @default.
• W2922249564 creator A5018821266 @default.
• W2922249564 creator A5019218337 @default.
• W2922249564 creator A5020087486 @default.
• W2922249564 creator A5033794128 @default.
• W2922249564 creator A5033956023 @default.
• W2922249564 creator A5036828560 @default.
• W2922249564 creator A5042260558 @default.
• W2922249564 creator A5046942922 @default.
• W2922249564 creator A5047631289 @default.
• W2922249564 creator A5054161290 @default.
• W2922249564 creator A5067154165 @default.
• W2922249564 creator A5067162282 @default.
• W2922249564 creator A5072546509 @default.
• W2922249564 creator A5081516283 @default.
• W2922249564 creator A5086730271 @default.
• W2922249564 creator A5089428686 @default.
• W2922249564 date "2019-06-27" @default.
• W2922249564 modified "2023-10-06" @default.
• W2922249564 title "Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia" @default.
• W2922249564 cites W1843407789 @default.
• W2922249564 cites W1986924929 @default.
• W2922249564 cites W1988682601 @default.
• W2922249564 cites W1999128869 @default.
• W2922249564 cites W2015299436 @default.
• W2922249564 cites W2063204645 @default.
• W2922249564 cites W2066564017 @default.
• W2922249564 cites W2076862756 @default.
• W2922249564 cites W2086296392 @default.
• W2922249564 cites W2091057822 @default.
• W2922249564 cites W2108206643 @default.
• W2922249564 cites W2120319857 @default.
• W2922249564 cites W2122479144 @default.
• W2922249564 cites W2140606816 @default.
• W2922249564 cites W2142099365 @default.
• W2922249564 cites W2156824251 @default.
• W2922249564 cites W2172242534 @default.
• W2922249564 cites W2173706097 @default.
• W2922249564 cites W2192121806 @default.
• W2922249564 cites W2213574133 @default.
• W2922249564 cites W2233614027 @default.
• W2922249564 cites W2369297677 @default.
• W2922249564 cites W2396328865 @default.
• W2922249564 cites W2516709103 @default.
• W2922249564 cites W2519500141 @default.
• W2922249564 cites W2573476619 @default.
• W2922249564 cites W2582864842 @default.
• W2922249564 cites W2604822177 @default.
• W2922249564 cites W2611243937 @default.
• W2922249564 cites W2787863642 @default.
• W2922249564 cites W2792666902 @default.
• W2922249564 cites W2808653175 @default.
• W2922249564 cites W2885605795 @default.
• W2922249564 cites W2891141671 @default.
• W2922249564 cites W2897902093 @default.
• W2922249564 cites W2902460563 @default.
• W2922249564 cites W2902706178 @default.
• W2922249564 cites W2904933400 @default.
• W2922249564 cites W3049379535 @default.
• W2922249564 cites W4293241248 @default.
• W2922249564 cites W60865865 @default.
• W2922249564 doi "https://doi.org/10.1182/blood-2019-01-896290" @default.
• W2922249564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6706803" @default.
• W2922249564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30862645" @default.
• W2922249564 hasPublicationYear "2019" @default.
• W2922249564 type Work @default.
• W2922249564 sameAs 2922249564 @default.
• W2922249564 citedByCount "55" @default.
• W2922249564 countsByYear W29222495642019 @default.
• W2922249564 countsByYear W29222495642020 @default.
• W2922249564 countsByYear W29222495642021 @default.
• W2922249564 countsByYear W29222495642022 @default.
• W2922249564 countsByYear W29222495642023 @default.
• W2922249564 crossrefType "journal-article" @default.
• W2922249564 hasAuthorship W2922249564A5000959540 @default.
• W2922249564 hasAuthorship W2922249564A5013649293 @default.
• W2922249564 hasAuthorship W2922249564A5013974745 @default.
• W2922249564 hasAuthorship W2922249564A5014844829 @default.
• W2922249564 hasAuthorship W2922249564A5016734314 @default.
• W2922249564 hasAuthorship W2922249564A5018821266 @default.
• W2922249564 hasAuthorship W2922249564A5019218337 @default.
• W2922249564 hasAuthorship W2922249564A5020087486 @default.
• W2922249564 hasAuthorship W2922249564A5033794128 @default.
• W2922249564 hasAuthorship W2922249564A5033956023 @default.
• W2922249564 hasAuthorship W2922249564A5036828560 @default.
• W2922249564 hasAuthorship W2922249564A5042260558 @default.
• W2922249564 hasAuthorship W2922249564A5046942922 @default.
• W2922249564 hasAuthorship W2922249564A5047631289 @default.
• W2922249564 hasAuthorship W2922249564A5054161290 @default.
• W2922249564 hasAuthorship W2922249564A5067154165 @default.
• W2922249564 hasAuthorship W2922249564A5067162282 @default.
• W2922249564 hasAuthorship W2922249564A5072546509 @default.

• next